Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

— Days after retaining the Nickles Group, Novo Nordisk also hired Checkmate Government Relations, the new D.C. outpost of a ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

The global obsession with weight-loss drugs is reaching unprecedented levels, reshaping industries, economies, and even our ...

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

The FDA says state-licensed compounding pharmacies must immediately stop making compound versions of GLP-1 drugs. Larger, national licensed facilities making compound versions of Zepbound have until ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS 5.26%), whose stock got devastated last week by worries that it ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

Blockbuster GLP-1 medications are changing patient care, impacting surgery volumes and reshaping the financial landscape of the healthcare industry.